Editorial
doi: 10.1097/gme.0b013e3181c615f6.
Bisphosphonate use in osteoporosis: cardiovascular effects
- PMID: 19934778
- DOI: 10.1097/gme.0b013e3181c615f6
Item in Clipboard
Editorial
Bisphosphonate use in osteoporosis: cardiovascular effects
Menopause.
2010 Jan-Feb.
No abstract available
Comment on
-
Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.Menopause. 2010 Jan-Feb;17(1):57-63. doi: 10.1097/gme.0b013e3181b34749. Menopause. 2010. PMID: 19680161
Similar articles
-
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].MMW Fortschr Med. 2009 Mar 5;151(10):7. MMW Fortschr Med. 2009. PMID: 19472655 German. No abstract available.
-
[Osteoporosis and bisphosphonates].Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8. Z Rheumatol. 2007. PMID: 17955251 German. No abstract available.
-
Yearly zoledronic acid in postmenopausal osteoporosis.N Engl J Med. 2007 Aug 16;357(7):711-2; author reply 714-5. N Engl J Med. 2007. PMID: 17703530 No abstract available.
-
Bisphosphonates and the risk of atrial fibrillation.Endokrynol Pol. 2011 Jan-Feb;62(1):93-6. Endokrynol Pol. 2011. PMID: 21365587 Review.
-
Bisphosphonates in the treatment of osteoporosis.Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9. Endocrinol Metab Clin North Am. 2012. PMID: 22877426 Review.
Cited by
-
Engineering endomorphin drugs: state of the art.Expert Opin Ther Pat. 2012 Jan;22(1):1-14. doi: 10.1517/13543776.2012.646261. Epub 2012 Jan 4. Expert Opin Ther Pat. 2012. PMID: 22214283 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
